A provider-focused update on the Aminosyn 3.5 % M, Sulfite Free shortage in 2026 — timeline, alternatives, prescribing implications, and tools.
The ongoing shortage of amino acid injection products continues to pose significant challenges for nutrition support teams, prescribers, and pharmacists across the United States. Aminosyn 3.5 % M, Sulfite Free — a peripheral-compatible crystalline amino acid solution with maintenance electrolytes manufactured by ICU Medical — has been intermittently affected by supply constraints that trace back to manufacturing limitations, raw material shortages, and quality-related disruptions.
This article provides a comprehensive update for providers on the current state of the shortage, its clinical and prescribing implications, available alternatives, and tools to help maintain continuity of care for your parenteral nutrition patients.
Amino acid injection products have experienced recurring shortages since at least 2014, with the ASHP maintaining an active shortage listing throughout this period. Key milestones include:
The shortage of Aminosyn 3.5 % M, Sulfite Free has several direct implications for prescribing and clinical practice:
Aminosyn 3.5 % M is one of the few amino acid formulations specifically designed for peripheral vein administration (osmolarity of 421 mOsmol/L when administered with 5-10% dextrose). If this product is unavailable and the patient is transitioned to a higher-concentration alternative (e.g., Travasol 10%, Clinisol 15%, or Plenamine 15%), central venous access will likely be required. This decision should be weighed against the patient's clinical status, expected duration of PN, and risk profile for central line complications.
Aminosyn 3.5 % M includes maintenance electrolytes (40 mEq/L sodium, 13 mEq/L potassium, 3 mEq/L magnesium, 3.5 mM phosphorus, 40 mEq/L chloride). Most alternative amino acid products — including Travasol, Clinisol, and Plenamine — do not contain electrolytes. When switching patients, the compounding pharmacy must add electrolytes individually, which requires updated orders and may alter the stability and compatibility profile of the final TPN admixture.
For patients with documented sulfite sensitivity, ensure any substitute product is also sulfite free. Clinisol 15% (Baxter) is sulfite free. Standard Aminosyn II formulations contain sodium hydrosulfite and are not suitable for sulfite-sensitive patients. Always verify the sulfite status of any alternative before prescribing.
As of early 2026, the availability landscape for amino acid injection products is as follows:
Providers can use Medfinder for Providers to check real-time availability of amino acid products across pharmacies and distributors.
Aminosyn 3.5 % M, Sulfite Free carries a wholesale cost of approximately $72 for 6,000 mL (six 1,000 mL bags). However, the total cost of PN therapy — including amino acids, dextrose, lipids, micronutrients, compounding, supplies, and clinical services — typically ranges from $200 to $500+ per day for home PN patients.
Key access and reimbursement considerations:
The following resources can help you manage the shortage and maintain quality care:
The amino acid injection shortage is a structural issue driven by market concentration (few manufacturers), manufacturing complexity, and supply chain fragility. While no new entrants to the U.S. market are imminent, ASPEN and ASHP continue to advocate for policy changes that would improve the resilience of the PN supply chain, including:
Managing parenteral nutrition during a shortage requires proactive communication, clinical flexibility, and reliable tools. Use Medfinder for Providers to help your patients find available products, stay current with ASHP and ASPEN shortage updates, and maintain clear documentation of shortage-related clinical decisions.
For additional resources, see our articles on helping patients find Aminosyn in stock, available alternatives, and helping patients manage PN costs.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
